Abstract
The Food and Drug Administration (FDA) on Oct. 11 approved the Secuado (asenapine) transdermal system, an atypical antipsychotic medication used to treat adults with schizophrenia. Secuado is the first and only FDA‐approved transdermal system for schizophrenia, Noven Pharmaceuticals officials stated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
